Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazioneAug. 29, 2017 - ESC 2017, Barcelona, Spain
The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.
These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
Prof. Filippo Crea is director, Department of Cardiovascular and Thoracic Science Catholic University of the Sacred Heart, Agostino Gemelli Hospital, Rome, Italy
Funding to produce this video was provided by an unrestricted educational grant from Novartis.